Dr Cheryl Barton
Freelance Journalist
Dr Barton is a freelance journalist specializing in the pharma and biotech sector.
Today's issue
Latest from Dr Cheryl Barton
Pharmaceutical
According to market research, the mitochondrial therapeutics market is valued at $2.32 billion in 2025. It is projected to reach $5.4 billion by 2035, growing at a CAGR of 8.8%, primarily driven by advances in gene therapy, enzyme replacement therapies and pharmacological agents, including drugs that modulate oxidative phosphorylation and mitochondrial biogenesis (Figure 1). 22 December 2025
Pharmaceutical
A Feature on M&A, VC investment, licensing and partnerships in the radiopharmaceuticals arena. 9 May 2025
Pharmaceutical
A Feature on M&A, VC investment licensing and partnerships focusing on novel targets in autoimmune diseases. 4 February 2025
Pharmaceutical
A Feature on M&A, licensing, and partnership tapping into AI’s potential to improve drug development. 2 December 2024
Biotechnology
A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new opportunities for pharma growth. 15 November 2024
Latest from Dr Cheryl Barton
Pharmaceutical
According to market research, the mitochondrial therapeutics market is valued at $2.32 billion in 2025. It is projected to reach $5.4 billion by 2035, growing at a CAGR of 8.8%, primarily driven by advances in gene therapy, enzyme replacement therapies and pharmacological agents, including drugs that modulate oxidative phosphorylation and mitochondrial biogenesis (Figure 1). 22 December 2025
Pharmaceutical
A Feature on M&A, VC investment, licensing and partnerships in the radiopharmaceuticals arena. 9 May 2025
Pharmaceutical
A Feature on M&A, VC investment licensing and partnerships focusing on novel targets in autoimmune diseases. 4 February 2025
Pharmaceutical
A Feature on M&A, licensing, and partnership tapping into AI’s potential to improve drug development. 2 December 2024
Biotechnology
A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new opportunities for pharma growth. 15 November 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
An Analysis of M&A activity in the CNS space. 26 July 2024
Pharmaceutical
An analysis of the investment activity of Novartis in recent years. 5 April 2024
Pharmaceutical
An analysis of recent pharma activity in the metabolic diseases field and why obesity is a hot topic amongst investors. 8 March 2024
Pharmaceutical
A feature analyzing recent pharma activity in the hepatology field and why NASH remains unchartered territory. 20 December 2023
Pharmaceutical
A feature analyzing how - and why - cardiology is of renewed interest to pharma. 17 November 2023
Biosimilars
A feature on recent market activity in the biosimilar sector. 18 September 2023
Pharmaceutical
A feature analyzing the recent investment activity in digital technologies and AI. 11 August 2023
Pharmaceutical
An analysis of recent mergers and acquisitions in the pharma sector. 3 July 2023
Biotechnology
A feature analyzing recent investment activity in cell and gene therapies. 9 June 2023
Pharmaceutical
A feature on the US drugmaker's drive to replace declining sales of the world's biggest-selling drug. 18 May 2023
Pharmaceutical
A Feature on recent investment activity in Asia-Pacific. 7 April 2023
Biotechnology
An analysis of the recent investment activity in antibody–drug conjugates (ADCs) prior to Pfizer's newly-announced $43 billion takeover of Seagen. 13 March 2023
Biotechnology
An analysis of the recent progress in RNA therapeutics and future opportunities. 31 January 2023
Pharmaceutical
An analysis of how - and why - ophthalmology is increasingly on pharma and investors' radar as a new growth area. 8 December 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze